CagriSema beats semaglutide at its own weight-loss game

Semaglutide changed the landscape of obesity treatment, and the obvious next question is whether pairing it with a second, complementary hormone signal works better still. CagriSema combines semaglutide, a GLP-1 receptor agonist, with cagrilintide, a long-acting amylin analogue, in a single fixed-dose injection. Individual trials had reported on it separately, so this review set out to pool them and ask whether the combination genuinely beats either drug on its own, and at what cost in side effects.

Following PRISMA and Cochrane guidance, the authors pooled seven randomised controlled trials covering 8,069 overweight or obese participants. CagriSema was compared against placebo, cagrilintide monotherapy and semaglutide monotherapy, with subgroup analyses splitting participants by type 2 diabetes status. Risk of bias was formally assessed for each trial and the certainty of the evidence was graded. Random effects models were used to combine the weight, blood sugar, lipid and safety outcomes across the trials.

CagriSema produced substantially more weight loss than every comparator: 13.99 kg more than placebo, 9.24 kg more than cagrilintide alone and 7.58 kg more than semaglutide alone. Lipid measures improved versus placebo, while blood sugar outcomes varied between trials and were harder to pin down. Adverse events were primarily gastrointestinal complaints and injection-site reactions, and there was no increase in serious adverse events. The authors describe the overall safety profile as favourable.

Beating placebo was expected; the notable result is the clear margin over semaglutide itself, one of the most effective obesity medicines currently available. That supports the idea that layering an amylin signal on top of a GLP-1 signal adds genuine effect rather than redundancy. The open questions are the long-term ones: whether the weight loss is durable, whether safety holds over years of use, and how the mixed blood sugar findings resolve. The authors call for large-scale trials to confirm long-term safety and durability.

For anyone following the rapid evolution of obesity medicine, this is a reason to think the next generation of treatments may go meaningfully beyond current GLP-1 drugs rather than merely matching them. It is pooled trial evidence with long-term durability still unproven, and these are prescription medicines with real side effects, chiefly gastrointestinal. The finding is informational: decisions about any of these drugs belong in a conversation with a clinician.